Zobrazeno 1 - 10
of 368
pro vyhledávání: '"59"'
Blockade of TRIM59 enhances esophageal cancer cell chemosensitivity to cisplatin by upregulating p53
Autor:
Zhi-Yu Wang, Rongfeng Liu, Hongchen Li, Jian Shi, Yanzhao Xu, Xing Li, Junfeng Liu, Yanzhi Cui, Xiaojin Guo
Publikováno v:
Oncology Letters
Human esophageal cancer (hESC) cell motility adopts various modes, resulting in hESC progression and poor survival. However, how tripartite motif 59 (TRIM59), as the ubiquitination machinery, participates in hESC metastasis is not completely understo
Autor:
Hiroki Ishihara, Takashi Ikeda, Hiroaki Shimmura, Toshio Takagi, Hideki Ishida, Kazunari Tanabe, Junpei Iizuka, Kazutaka Nakamura, Hidekazu Tachibana, Kazuhiko Yoshida, Hirohito Kobayashi, Hironori Fukuda, Yasunobu Hashimoto, Tsunenori Kondo, Yuki Nemoto
Publikováno v:
Targeted Oncology. 16:493-502
It remains unclear how early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events affects the outcome of previously untreated metastatic renal cell carcinoma (mRCC). To investigate the prognostic impact of the earl
Autor:
Yasin Tuncer, Rahime Özdemir
Publikováno v:
Molecular Biology Reports. 47:1703-1712
The aim of this study was isolation and identification of the high-level aminoglycoside-resistant (HLAR) enterococci in raw milk and dairy products and to analyze their antibiotic resistance and the presence of aminoglycoside-modifying enzyme (AME) g
Autor:
Rachel M. Layman, Giuseppe Curigliano, Adam S. Crystal, C Terret, Serena Liao, Komal Jhaveri, Sara Cresta, Yan Ji, N Kundamal, Yoon Sim Yap, François Duhoux, Dejan Juric
Publikováno v:
Cancer Research. 80:PD7-09
Background: The combination of ribociclib (an oral CDK4/6 inhibitor) and ET improved survival outcomes in patients (pts) with ER+ ABC in comparison to single-agent ET. In preclinical models, LSZ102 (an experimental oral SERD) demonstrated synergistic
Autor:
Luciana Kikuchi, Alice M. Isejima, Paulo M. Hoff, Marcelo Queiroz, Leonardo Gomes da Fonseca, Maria Ignez Braghiroli, Joao Glasberg, Christian Kappeler, Luiz Antonio Senna Leite, Daniela R. Nebuloni, Giovanni M. Bariani, Rachel P. Riechelmann, Thomas Giollo Rivelli
Publikováno v:
The Oncologist. 24:1180-1187
Background Regorafenib is a multikinase inhibitor with antiangiogenic effects that improves overall survival (OS) in metastatic colorectal cancer (mCRC) after failure of standard therapies. We investigated the efficacy and safety of regorafenib in an
Autor:
Takashi Seto, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Chia-Chi Lin, Sai-Hong Ignatius Ou, Jill S. Clancy, Joseph Chen, Gregory J. Riely, Eng Huat Tan, Holger Thurm, Todd M. Bauer, Gerson Peltz, D. Ross Camidge, Leonard P. James, Rita Chiari, Alessandra Bearz, Benjamin Solomon, Enriqueta Felip, Ross A. Soo, Antonello Abbattista, Jean-Francois Martini
Publikováno v:
The Lancet Oncology. 19:1654-1667
Summary Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung canc
Autor:
Marlinde L. van den Boogaard, Helen N. Pemberton, Jennifer R. Tall, Sabine Hartlieb, Helen E. Bryant, James Campbell, Barbara Martins da Costa, Sally L. George, Christopher J. Lord, Federica Lorenzi, Louis Chesler, Umut H. Toprak, David A. King, Jan J. Molenaar, Karen Barker, M. Emmy M. Dolman, Frank Westermann
Publikováno v:
EBioMedicine, Vol 59, Iss, Pp 102971-(2020)
EBioMedicine
EBioMedicine, 59. Elsevier BV
EBioMedicine
EBioMedicine, 59. Elsevier BV
Background In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup. Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research. Methods To evaluate the impact o
Autor:
Kang-Yi Su, Kun-Chieh Chen, Gee-Chen Chang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Jeng-Sen Tseng, Yen-Hsiang Huang, Sung-Liang Yu
Publikováno v:
Scientific Reports
It remains unclear how programmed death-ligand 1 (PD-L1) expression interacts with anaplastic lymphoma kinase (ALK) mutation, its variants, and the outcome of treatment. One hundred and twenty four out of 1255 patients (9.9%) were deemed ALK-positive
Autor:
Daria S. Chulpanova, Ekaterina Garanina, Svetlana F. Khaiboullina, Marina O. Gomzikova, Elvira R. Akhmetzyanova, Svetlana S. Arkhipova, Valeriya V. Solovyeva, Victoria James, Albert A. Rizvanov, Leysan G. Tazetdinova
Publikováno v:
Bioengineering
Volume 7
Issue 2
Bioengineering, Vol 7, Iss 59, p 59 (2020)
Volume 7
Issue 2
Bioengineering, Vol 7, Iss 59, p 59 (2020)
High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal cell carcinoma and metastatic melanoma. However, systemic administration of high doses of IL2 can be toxic, causing capillary leakage syndrome and stimulating
Autor:
Quirijn de Mast, Marissa L. Maciej-Hulme, Johan van der Vlag, Cansu Yanginlar, Baranca Buijsers
Publikováno v:
Ebiomedicine, 59
EBioMedicine
EBioMedicine, Vol 59, Iss, Pp 102969-(2020)
EBioMedicine
EBioMedicine, Vol 59, Iss, Pp 102969-(2020)
Contains fulltext : 225474.pdf (Publisher’s version ) (Open Access) Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd7c5396dd901a4949b6d3a0ad33bc4
https://hdl.handle.net/2066/225474
https://hdl.handle.net/2066/225474